Literature DB >> 16216651

Resistance to antibiotics: are we in the post-antibiotic era?

Alfonso J Alanis1.   

Abstract

Serious infections caused by bacteria that have become resistant to commonly used antibiotics have become a major global healthcare problem in the 21st century. They not only are more severe and require longer and more complex treatments, but they are also significantly more expensive to diagnose and to treat. Antibiotic resistance, initially a problem of the hospital setting associated with an increased number of hospital-acquired infections usually in critically ill and immunosuppressed patients, has now extended into the community causing severe infections difficult to diagnose and treat. The molecular mechanisms by which bacteria have become resistant to antibiotics are diverse and complex. Bacteria have developed resistance to all different classes of antibiotics discovered to date. The most frequent type of resistance is acquired and transmitted horizontally via the conjugation of a plasmid. In recent times new mechanisms of resistance have resulted in the simultaneous development of resistance to several antibiotic classes creating very dangerous multidrug-resistant (MDR) bacterial strains, some also known as "superbugs". The indiscriminate and inappropriate use of antibiotics in outpatient clinics, hospitalized patients and in the food industry is the single largest factor leading to antibiotic resistance. In recent years, the number of new antibiotics licensed for human use in different parts of the world has been lower than in the recent past. In addition, there has been less innovation in the field of antimicrobial discovery research and development. The pharmaceutical industry, large academic institutions or the government are not investing the necessary resources to produce the next generation of newer safe and effective antimicrobial drugs. In many cases, large pharmaceutical companies have terminated their anti-infective research programs altogether due to economic reasons. The potential negative consequences of all these events are relevant because they put society at risk for the spread of potentially serious MDR bacterial infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216651     DOI: 10.1016/j.arcmed.2005.06.009

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  265 in total

1.  Multidrug-resistant organisms, wounds and topical antimicrobial protection.

Authors:  Philip G Bowler; Sarah Welsby; Victoria Towers; Rebecca Booth; Andrea Hogarth; Victoria Rowlands; Alexis Joseph; Samantha A Jones
Journal:  Int Wound J       Date:  2012-05-29       Impact factor: 3.315

2.  Do we need new antibiotics? The search for new targets and new compounds.

Authors:  Jaroslav Spížek; Jitka Novotná; Tomáš Rezanka; Arnold L Demain
Journal:  J Ind Microbiol Biotechnol       Date:  2010-11-18       Impact factor: 3.346

3.  Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins.

Authors:  Xiaoxi Lu; Ting Chan; Chenghao Xu; Ling Zhu; Qi Tony Zhou; Kade D Roberts; Hak-Kim Chan; Jian Li; Fanfan Zhou
Journal:  J Antimicrob Chemother       Date:  2015-10-22       Impact factor: 5.790

Review 4.  War on terror cells: killing the host that harbours 'superbugs' is an infection control strategy in our fight against infectious diseases.

Authors:  Naveed Ahmed Khan; Ruqaiyyah Siddiqui
Journal:  Pathog Glob Health       Date:  2014-01-14       Impact factor: 2.894

5.  Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa.

Authors:  Tim Holm Jakobsen; Steinn Kristinn Bragason; Richard Kerry Phipps; Louise Dahl Christensen; Maria van Gennip; Morten Alhede; Mette Skindersoe; Thomas Ostenfeld Larsen; Niels Høiby; Thomas Bjarnsholt; Michael Givskov
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

6.  Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrug-resistant nosocomial bacterial strains.

Authors:  Maria Luisa Mangoni; Giuseppantonio Maisetta; Mariagrazia Di Luca; Ludovica Marcellini Hercolani Gaddi; Semih Esin; Walter Florio; Franca Lisa Brancatisano; Donatella Barra; Mario Campa; Giovanna Batoni
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

7.  The innate growth bistability and fitness landscapes of antibiotic-resistant bacteria.

Authors:  J Barrett Deris; Minsu Kim; Zhongge Zhang; Hiroyuki Okano; Rutger Hermsen; Alexander Groisman; Terence Hwa
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

8.  Gold Nanoparticles with Antibiotic-Metallopolymers toward Broad-Spectrum Antibacterial Effects.

Authors:  Peng Yang; Parasmani Pageni; Md Anisur Rahman; Marpe Bam; Tianyu Zhu; Yung Pin Chen; Mitzi Nagarkatti; Alan W Decho; Chuanbing Tang
Journal:  Adv Healthc Mater       Date:  2018-11-27       Impact factor: 9.933

9.  The meaningful use of EMR in Chinese hospitals: a case study on curbing antibiotic abuse.

Authors:  Jing-Song Li; Xiao-Guang Zhang; Hua-Qiong Wang; Yu Wang; Jing-Ming Wang; Qing-Dong Shao
Journal:  J Med Syst       Date:  2013-03-14       Impact factor: 4.460

Review 10.  The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Borna Müller; Sonia Borrell; Graham Rose; Sebastien Gagneux
Journal:  Trends Genet       Date:  2012-12-13       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.